International Edition
World Markets FX Policy

Friday, 9 October 2026

Private Trade News

Global markets, trading & world business — for professional traders

Trading

Alumis Reports Positive Phase 3 Data With Envudeucitinib

Cross-asset desk, Private Trade News (2026-10-09): Alumis Reports Positive Phase 3 Data With Envudeucitinib (RTTNews) - Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical… Primary source: original at Nasdaq Market Structure (nasdaq.com).

· Nasdaq Market Structure

Alumis Reports Positive Phase 3 Data With Envudeucitinib

(RTTNews) - Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3. The company said the results reinforced the potential of envudeucitinib to become a leading oral therapy for patients with moder

Read at source

Read also